amphetamine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 15 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using the excitotoxic animal model of Huntington's disease, two experimental treatments were evaluated." | 1.28 | Neural grafts and pharmacological intervention in a model of Huntington's disease. ( Ford, LM; Giordano, M; Sanberg, PR; Shipley, MT, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorner, JL | 1 |
| Miller, BR | 1 |
| Klein, EL | 1 |
| Murphy-Nakhnikian, A | 1 |
| Andrews, RL | 1 |
| Barton, SJ | 1 |
| Rebec, GV | 1 |
| Ortiz, AN | 1 |
| Osterhaus, GL | 1 |
| Lauderdale, K | 1 |
| Mahoney, L | 1 |
| Fowler, SC | 1 |
| von Hörsten, S | 1 |
| Riess, O | 1 |
| Johnson, MA | 1 |
| Ayalon, L | 1 |
| Doron, R | 1 |
| Weiner, I | 1 |
| Joel, D | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Pineda, JR | 1 |
| Canals, JM | 1 |
| Bosch, M | 1 |
| Adell, A | 1 |
| Mengod, G | 1 |
| Artigas, F | 1 |
| Ernfors, P | 1 |
| Alberch, J | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Hays, SE | 1 |
| Goodwin, FK | 1 |
| Paul, SM | 1 |
| Popoli, P | 1 |
| Pèzzola, A | 1 |
| Reggio, R | 1 |
| Caporali, MG | 1 |
| Scotti de Carolis, A | 1 |
| Carolei, A | 1 |
| Del Castillo, G | 1 |
| Klawans, HL | 3 |
| Weiner, WJ | 2 |
| Lamprecht, F | 1 |
| Giordano, M | 1 |
| Ford, LM | 1 |
| Shipley, MT | 1 |
| Sanberg, PR | 1 |
| Birkmayer, W | 1 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
5 reviews available for amphetamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
[Recent neurobiological and related pharmaco-therapeutic acquisitions in Huntington's chorea].
Topics: Amphetamine; Antipsychotic Agents; Brain; Butyrophenones; gamma-Aminobutyric Acid; Humans; Huntingto | 1979 |
The pharmacology of choreatic movement disorders.
Topics: Acetylcholine; Acute Disease; Amphetamine; Chorea; Dopamine; gamma-Aminobutyric Acid; Hepatolenticul | 1976 |
Epilepsy and schizophrenia: a neurochemical bridge.
Topics: Amphetamine; Anticonvulsants; Brain; Butyrophenones; Disulfiram; Dopamine; Dopamine beta-Hydroxylase | 1977 |
Pathophysiology of schizophrenia and the striatum.
Topics: Adult; Amphetamine; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Dihydroxyphenylalanine; Dopa | 1972 |
1 trial available for amphetamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
[10 years of L-DOPA therapy of Parkinson's syndrome].
Topics: Administration, Oral; Amphetamine; Animals; Brain Chemistry; Catecholamines; Clinical Trials as Topi | 1971 |
9 other studies available for amphetamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Ascorbic Acid; Cerebral Cortex; Corpus Striatum; Disease | 2009 |
Motor function and dopamine release measurements in transgenic Huntington's disease model rats.
Topics: Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Huntingto | 2012 |
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cognition; D | 2004 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
Topics: Amphetamine; Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine | 2005 |
Cholecystokinin receptors in brain: effects of obesity, drug treatment, and lesions.
Topics: Amphetamine; Animals; Brain; Caudate Nucleus; Fasting; Humans; Huntington Disease; In Vitro Techniqu | 1981 |
CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease.
Topics: Adenosine; Amphetamine; Animals; Disease Models, Animal; Huntington Disease; Male; Motor Activity; P | 1994 |
Neural grafts and pharmacological intervention in a model of Huntington's disease.
Topics: Acetylcholinesterase; Amphetamine; Animals; Brain Tissue Transplantation; Catalepsy; Cerebral Cortex | 1990 |
Lingual-facial-buccal movements in the elderly. I. Pathophysiology and treatment.
Topics: Aged; Amphetamine; Chemoreceptor Cells; Chlorpromazine; Corpus Striatum; Dopamine Antagonists; Facia | 1973 |